HH Biotechnology Holdings Company
HHBTOTCReal Estate● Active
$0.00
+$0.00(+0.00%)
Market Cap$1406
P/E Ratio—
52W High$0.0002
52W Low$0.0001
HH Biotechnology Holdings Company (HHBT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HHBT · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2015-12 |
|---|---|
| Revenue | |
| Revenue | $7.99M |
| Cost of Revenue | $5.64M |
| Gross Profit | $2.35M |
| Gross Margin %(computed) | 29.45% |
| Operating Expenses | |
| R&D Expenses | $0.00M |
| G&A Expenses | $0.00M |
| Total Operating Expenses | ($0.75M) |
| Operating Income | $3.10M |
| Operating Margin %(computed) | 38.78% |
| Interest Income | $0.00M |
| Interest Expense | $0.87M |
| Income Before Tax | $2.66M |
| Income Tax Expense | $0.23M |
| Net Income | $2.48M |
| Net Margin %(computed) | 30.99% |
| Per Share & EBITDA | |
| EPS (Basic) | $0.18 |
| Wtd Avg Shares | 13.52M |
| EBITDA | $5.44M |
| EBITDA Margin %(computed) | 68.13% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more HH Biotechnology Holdings Company data
About HH Biotechnology Holdings Company (HHBT) Income Statement
HH Biotechnology Holdings Company (HHBT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2015, HHBT reported revenue of $0.01B, gross profit of $0.00B (gross margin 29.45%), and net income of $0.00B — a net profit margin of 30.99%.
Frequently asked questions
HHBT · 4 questionsHH Biotechnology Holdings Company (HHBT) reported revenue of $0.01B for 2015, down —% year-over-year.
HHBT revenueHHBT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09